Phase 3 Clinical Trials With Primary Completion Dates in February 2023

This is a list of Phase 3 trials with primary completion dates in February 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ALIDAllied Corp.2023-02-01Phase 3NCT04750070Management of Shock in Children With SAM or Severe Underweight and Diarrhea
ALVOAlvotech2023-02-01Phase 3NCT05155293Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
BTAIBioXcel Therapeutics, Inc.2023-02-01Phase 3NCT05271552Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
CERECerevel Therapeutics Holdings, Inc.2023-02-01Phase 3NCT04542499Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
CSTLCastle Biosciences, Inc.2023-02-01Phase 3NCT04213261A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
CYDYCytoDyn Inc.2023-02-01Phase 3NCT04901689Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
JAZZJazz Pharmaceuticals plc2023-02-01Phase 3NCT04203498Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
MGCLFMGC Pharmaceuticals Limited2023-02-01Phase 3NCT04802382Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
TVTXTravere Therapeutics, Inc.2023-02-01Phase 3NCT03493685Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
URGNUroGen Pharma Ltd.2023-02-01Phase 3NCT05243550A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer